The estimated Net Worth of Timothy Kennedy is at least $853 Thousand dollars as of 19 October 2016. Mr. Kennedy owns over 36,363 units of Biocept Inc stock worth over $26,687 and over the last 8 years he sold BIOC stock worth over $0. In addition, he makes $826,508 as Chief Financial Officer, Senior Vice President - Operations, and Corporate Secretary at Biocept Inc.
Timothy has made over 1 trades of the Biocept Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 36,363 units of BIOC stock worth $39,999 on 19 October 2016.
The largest trade he's ever made was buying 36,363 units of Biocept Inc stock on 19 October 2016 worth over $39,999. On average, Timothy trades about 4,545 units every 0 days since 2016. As of 19 October 2016 he still owns at least 61,363 units of Biocept Inc stock.
You can see the complete history of Mr. Kennedy stock trades at the bottom of the page.
Timothy C. Kennedy serves as Chief Financial Officer, Senior Vice President - Operations, Corporate Secretary of the Company. Mr. Kennedy has over 30 years of executive, financial, and operational leadership experience, with over 25 years in the clinical diagnostics industry. Mr. Kennedy previously served as Chief Financial Officer of Millennium Health, a privately held leading urine drug testing and pharmacogenetics laboratory company, from 2013 to July 2016. Prior to joining Millennium Health, Mr. Kennedy was Chief Financial Officer and General Manager of PLUS Diagnostics, a urology, gastroenterology and oncology lab from 2008 through 2012. Prior to Plus Diagnostics, Mr. Kennedy held an ownership position in Diagnostic Imaging Management, a multi-site imaging company from 1997 to 2008, expanding from 12 to 33 free-standing centers across the United States. From 1988 to 1997, Mr. Kennedy held a number of management positions with National Health Laboratories, where he served as the Head of Finance, completing over 50 acquisitions and the merger with Roche Biomedical Labs to form LabCorp in 1995. Mr. Kennedy serves on the Board of Directors of MyCircle Health, a data services company that helps patients with chronic health conditions measure, evaluate, control and communicate daily test results to their healthcare providers and physicians. Mr. Kennedy holds a bachelor’s degree in Business - Accounting/Information Technology from Keane University.
As the Chief Financial Officer, Senior Vice President - Operations, and Corporate Secretary of Biocept Inc, the total compensation of Timothy Kennedy at Biocept Inc is $826,508. There are 1 executives at Biocept Inc getting paid more, with Michael Nall having the highest compensation of $1,216,060.
Timothy Kennedy is 62, he's been the Chief Financial Officer, Senior Vice President - Operations, and Corporate Secretary of Biocept Inc since 2016. There are 11 older and 7 younger executives at Biocept Inc. The oldest executive at Biocept Inc is Margaret Faye Wilson, 82, who is the Lead Independent Director.
Timothy's mailing address filed with the SEC is C/O BIOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO, CA, 92121.
Over the last 11 years, insiders at Biocept Inc have traded over $2,456 worth of Biocept Inc stock and bought 1,703,300 units worth $1,869,312 . The most active insiders traders include Claire Reiss, Edward A. Neff, and David F Hale. On average, Biocept Inc executives and independent directors trade stock every 92 days with the average trade being worth of $27,462. The most recent stock trade was executed by David F Hale on 9 December 2021, trading 445 units of BIOC stock currently worth $1,807.
biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor associated dna , both in circulating tumor cells (ctcs) and in plasma (cell free circulating tumor dna). our mission is to improve outcomes for cancer patients by advancing oncology diagnostics. we utilize patented and innovative technologies to deliver clinically relevant oncology diagnostics to physicians by providing advanced prognostic and predictive assessments for guiding the course of treating patients. additionally, we offer services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies, and clinical trial support. our strategic focus is to promote our unique targeted selector™ technology to the oncology community. our target selector technology has demonstrated that it can consistently capture extremely rare cells which may be present in only 1 of every 50-100 billion blood cells. examples of these rare cells ar
Biocept Inc executives and other stock owners filed with the SEC include: